What Happened
The past week has seen significant developments in healthcare policy and research. President Trump announced a drug-pricing agreement with Regeneron, marking the last of 17 deals sought by the White House. Meanwhile, the use of guest editors in scientific journals has raised concerns about the integrity of research, with a genetics journal retracting nearly an entire special issue due to problematic editing practices.
Psychedelics Get a Boost
The White House has given a boost to psychedelics research, with President Trump signing an executive order to support the development of psychedelic treatments. This move has been welcomed by researchers and advocates, who see psychedelics as a potential game-changer for mental health treatment.
Vaccination Efforts Bear Fruit
A massive catch-up initiative has delivered over 100 million childhood vaccinations across 36 countries, helping to narrow critical immunity gaps. The Big Catch-Up (BCU) program, led by Gavi, the Vaccine Alliance, WHO, and UNICEF, has reached an estimated 18.3 million children aged 1 to 5, providing them with life-saving vaccines.
Assisted Dying Bill Stalls
A proposed law to legalize assisted dying in England and Wales has run out of time to become law, despite support from MPs. The bill has stalled in the House of Lords, with critics arguing that it does not have sufficient safeguards to protect vulnerable people. Supporters have vowed to continue the fight, confident that the legislation will return in the next session of Parliament.
Key Numbers
- **100 million: The number of childhood vaccinations delivered through the Big Catch-Up program.
Key Facts
- What: Drug-pricing agreement, psychedelics research, vaccination efforts, assisted dying bill.
- When: Recent weeks and months.
- Impact: Potential changes to healthcare policy and research, improved vaccination rates, and ongoing debate over assisted dying.
What Experts Say
"This is a significant step forward for psychedelics research, and we're excited to see where this will lead." — Daniel Payne, STAT Washington correspondent
What Comes Next
As the healthcare landscape continues to evolve, we can expect further developments in medical marijuana, psychedelics, and vaccination efforts. The stalled assisted dying bill may return in the next session of Parliament, and researchers will be watching closely to see how the White House's psychedelics executive order will impact their work.
What Happened
The past week has seen significant developments in healthcare policy and research. President Trump announced a drug-pricing agreement with Regeneron, marking the last of 17 deals sought by the White House. Meanwhile, the use of guest editors in scientific journals has raised concerns about the integrity of research, with a genetics journal retracting nearly an entire special issue due to problematic editing practices.
Psychedelics Get a Boost
The White House has given a boost to psychedelics research, with President Trump signing an executive order to support the development of psychedelic treatments. This move has been welcomed by researchers and advocates, who see psychedelics as a potential game-changer for mental health treatment.
Vaccination Efforts Bear Fruit
A massive catch-up initiative has delivered over 100 million childhood vaccinations across 36 countries, helping to narrow critical immunity gaps. The Big Catch-Up (BCU) program, led by Gavi, the Vaccine Alliance, WHO, and UNICEF, has reached an estimated 18.3 million children aged 1 to 5, providing them with life-saving vaccines.
Assisted Dying Bill Stalls
A proposed law to legalize assisted dying in England and Wales has run out of time to become law, despite support from MPs. The bill has stalled in the House of Lords, with critics arguing that it does not have sufficient safeguards to protect vulnerable people. Supporters have vowed to continue the fight, confident that the legislation will return in the next session of Parliament.
Key Numbers
- **100 million: The number of childhood vaccinations delivered through the Big Catch-Up program.
Key Facts
- What: Drug-pricing agreement, psychedelics research, vaccination efforts, assisted dying bill.
- When: Recent weeks and months.
- Impact: Potential changes to healthcare policy and research, improved vaccination rates, and ongoing debate over assisted dying.
What Experts Say
"This is a significant step forward for psychedelics research, and we're excited to see where this will lead." — Daniel Payne, STAT Washington correspondent
What Comes Next
As the healthcare landscape continues to evolve, we can expect further developments in medical marijuana, psychedelics, and vaccination efforts. The stalled assisted dying bill may return in the next session of Parliament, and researchers will be watching closely to see how the White House's psychedelics executive order will impact their work.